Celldex Therapeutics, Inc (CLDX) is a publicly traded Healthcare sector company. As of July 16, 2026, CLDX trades at $38.48 with a market cap of $3.00B and a P/E ratio of -9.90. CLDX moved +0.29% today. Year to date, CLDX is +41.05%; over the trailing twelve months it is +67.66%. Its 52-week range spans $14.40 to $40.30. Analyst consensus is strong buy with an average price target of $51.10. Rallies surfaces CLDX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies community data for CLDX shows anonymized retail investor ownership, positioning, sentiment, and portfolio context when enough community data is available.
| Metric | Value |
|---|---|
| Price | $38.48 |
| Market Cap | $3.00B |
| P/E Ratio | -9.90 |
| EPS | $-3.90 |
| Dividend Yield | 0.00% |
| 52-Week High | $40.30 |
| 52-Week Low | $14.40 |
| Volume | 420.00K |
| Avg Volume | 0 |
| Revenue (TTM) | $1.54M |
| Net Income | $-258.76M |
| Gross Margin | 87.06% |
11 analysts cover CLDX: 0 strong buy, 10 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $51.10.